Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases-Randomized Placebo-Controlled Multicenter Trial.
Crohn’s disease
sodium butyrate
ulcerative colitis
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
11 Aug 2022
11 Aug 2022
Historique:
received:
16
06
2022
revised:
06
08
2022
accepted:
10
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Butyric acid's effectiveness has not yet been assessed in the pediatric inflammatory bowel disease (IBD) population. This study aimed to evaluate the effectiveness of oral sodium butyrate as an add-on to standard therapy in children and adolescents with newly diagnosed IBD. This was a prospective, randomized, placebo-controlled multicenter study. Patients aged 6-18 years with colonic Crohn's disease or ulcerative colitis, who received standard therapy depending on the disease's severity, were randomized to receive 150 mg sodium butyrate twice a day (group A) or placebo (group B). The primary outcome was the difference in disease activity and fecal calprotectin concentration between the two study groups measured at 12 weeks of the study. In total, 72 patients with initially active disease completed the study, 29 patients in group A and 43 in group B. At week 12 of the study, the majority of patients achieved remission. No difference in remission rate or median disease activity was found between the two groups ( A 12-week supplementation with sodium butyrate, as adjunctive therapy, did not show efficacy in newly diagnosed children and adolescents with IBD.
Sections du résumé
BACKGROUND
BACKGROUND
Butyric acid's effectiveness has not yet been assessed in the pediatric inflammatory bowel disease (IBD) population. This study aimed to evaluate the effectiveness of oral sodium butyrate as an add-on to standard therapy in children and adolescents with newly diagnosed IBD.
METHODS
METHODS
This was a prospective, randomized, placebo-controlled multicenter study. Patients aged 6-18 years with colonic Crohn's disease or ulcerative colitis, who received standard therapy depending on the disease's severity, were randomized to receive 150 mg sodium butyrate twice a day (group A) or placebo (group B). The primary outcome was the difference in disease activity and fecal calprotectin concentration between the two study groups measured at 12 weeks of the study.
RESULTS
RESULTS
In total, 72 patients with initially active disease completed the study, 29 patients in group A and 43 in group B. At week 12 of the study, the majority of patients achieved remission. No difference in remission rate or median disease activity was found between the two groups (
CONCLUSIONS
CONCLUSIONS
A 12-week supplementation with sodium butyrate, as adjunctive therapy, did not show efficacy in newly diagnosed children and adolescents with IBD.
Identifiants
pubmed: 36014789
pii: nu14163283
doi: 10.3390/nu14163283
pmc: PMC9414716
pii:
doi:
Substances chimiques
Butyric Acid
107-92-6
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Pharm. 2002 Jan 1;231(1):83-95
pubmed: 11719017
Gut Microbes. 2021 Jan-Dec;13(1):1968257
pubmed: 34494943
Prz Gastroenterol. 2020;15(2):119-125
pubmed: 32550943
Nutrients. 2022 Apr 17;14(8):
pubmed: 35458231
Neurogastroenterol Motil. 2020 Oct;32(10):e13914
pubmed: 32476236
Dig Dis Sci. 2000 May;45(5):976-81
pubmed: 10795763
Pharmacol Res. 2020 Sep;159:104947
pubmed: 32492488
Animals (Basel). 2020 Jul 07;10(7):
pubmed: 32645998
Diagn Microbiol Infect Dis. 2013 Mar;75(3):245-51
pubmed: 23276768
Minerva Gastroenterol Dietol. 2008 Sep;54(3):231-8
pubmed: 18614971
J Pediatr Gastroenterol Nutr. 1991 May;12(4):439-47
pubmed: 1678008
Neurogastroenterol Motil. 2021 Jan;33(1):e14038
pubmed: 33222317
World J Gastroenterol. 2011 Mar 28;17(12):1519-28
pubmed: 21472114
Aliment Pharmacol Ther. 2005 Nov 1;22(9):789-94
pubmed: 16225487
World J Gastroenterol. 2007 Feb 21;13(7):1079-84
pubmed: 17373743
Br J Pharmacol. 2017 Jun;174(11):1484-1496
pubmed: 27684049
Cells. 2021 Jul 14;10(7):
pubmed: 34359944
EBioMedicine. 2018 Apr;30:317-325
pubmed: 29627390
Complement Med Res. 2021;28(4):344-356
pubmed: 33352566
J Crohns Colitis. 2019 Sep 27;13(10):1351-1361
pubmed: 30919886
Aliment Pharmacol Ther. 2008 Jan 15;27(2):104-19
pubmed: 17973645
Front Microbiol. 2018 Sep 25;9:2247
pubmed: 30319571
J Nutr Biochem. 2012 May;23(5):430-6
pubmed: 21658926
Inflamm Bowel Dis. 2018 Feb 15;24(3):558-572
pubmed: 29462379
Gastroenterology. 2007 Aug;133(2):423-32
pubmed: 17681163
J Clin Med. 2020 Dec 04;9(12):
pubmed: 33291846
Scand J Gastroenterol. 2002 Apr;37(4):458-66
pubmed: 11989838
Biology (Basel). 2022 Jan 10;11(1):
pubmed: 35053106